CRYBA1

Across TCGA pan-cancer cohorts, CRYBA1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CRYBA1 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CRYBA1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CRYBA1 expression acts as an unfavorable survival marker.

PDAC, LUAD, and CCRCC are the cancer types where CRYBA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.418	0.639	.020	19	view →
LUAD	OS	Quartile	All	0.681	0.895	.004	16	view →
CCRCC	DFS	Median	All	0.704	1.000	.008	6	view →
GBM	DFS	Median	All	0.638	0.852	.011	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CRYBA1–PDAC (OS)

Open the PDAC breakdown →